In a promising phase 1/2 trial (NCT03056339), researchers developed allogeneic CD19 CAR-NK cells derived from cord blood to treat patients with relapsed or refractory non-Hodgkin’s lymphoma or chronic lymphocytic leukemia (CLL). Here, CD19 is linked to non-Hodgkin lymphoma.